Pre-Made Nonacog Gamma Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 for drug discovery and mechanism of action (MOA) research

Pre-Made Nonacog Gamma Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nonacog gamma is a new recombinant factor IX to treat factor IX deficiency. It is indicated for control of bleeding, perioperative management and routine prophylaxis to prevent or reduce the frequency of bleeding in adults and children with hemophilia B.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-929-1mg	1mg	3090
GMP-Bios-INN-929-10mg	10mg	Inquiry
GMP-Bios-INN-929-100mg	100mg	Inquiry
GMP-Bios-INN-929-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Nonacog Gamma Biosimilar, Recombinant Protein targeting F9: Recombinant therapeutic protein targeting FIX/P19/PTC/HEMB/THPH8
INN Name	Nonacog Gamma
Target	F9
Format	Recombinant Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	F9 (coagulation factor 9, coagulation factor IX) recombinant (variant_011773) glycosylated (glycoform alfa)
VD LC	F9 (coagulation factor 9, coagulation factor IX) recombinant (variant_011773) glycosylated (glycoform alfa)
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Baxter BioScience (Westlake Village CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0